ADVAIR 250 MCG
FLUTICASONE PROPIONATE : 250 MCG SALMETEROL (SALMETEROL XINAFOATE) : 25 MCG · DIN 02245127 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is ADVAIR?
ADVAIR 250 MCG contains FLUTICASONE PROPIONATE : 250 MCG SALMETEROL (SALMETEROL XINAFOATE) : 25 MCG. It is listed in the Health Canada Drug Product Database under DIN 02245127, held by GLAXOSMITHKLINE INC, supplied as AEROSOL, METERED DOSE for INHALATION administration. Health Canada currently lists it as marketed, status dated 21-Dec-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ADVAIR used for?
ADVAIR /ADVAIR DISKUS (fluticasone propionate/salmeterol) is a combination of an inhaled corticosteroid (ICS) and a long - acting beta 2 - adrenergic agonist (LABA) indicated for the maintenance treatment of asthma, in patients with reversible obstructive airways disease. ADVAIR/ADVAIR DISKUS should be prescribed for patients not adequately controlled on a long - term asthma control medication, such as an ICS, or whose disease severity clearly warrants treatment with both an IC S and a LABA. ADVAIR DISKUS 250 and ADVAIR DISKUS 500 are indicated for the maintenance treatment of COPD, including emphysema and chronic bronchitis, in patients where the use of a combination product is considered appropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02245127 |
|---|---|
| Brand name | ADVAIR |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 250 MCG SALMETEROL (SALMETEROL XINAFOATE) : 25 MCG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 250 MCG |
| Dosage form | AEROSOL, METERED DOSE |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03AK06 SALMETEROL AND FLUTICASONE |
| AHFS class | 56:10.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Dec-2001 |
| Original market date | 2003-06-16 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code R03AK06 SALMETEROL AND FLUTICASONE. 11 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADVAIR | 125MCG | AEROSOL, METERED DOSE | GLAXOSMITHKLINE INC | MARKETED | DIN 02245126 |
| ADVAIR 100 DISKUS | 50 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02240835 |
| ADVAIR 250 DISKUS | 250 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02240836 |
| ADVAIR 500 DISKUS | 50 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02240837 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494507 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494515 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494523 |
| WIXELA INHUB | 250 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495600 |
| WIXELA INHUB | 50 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495619 |
| WIXELA INHUB | 50 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495597 |
Who else supplies SALMETEROL AND FLUTICASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SALMETEROL AND FLUTICASONE appears in 77 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.